← Leaderboards
Michael D Gunn
Duke University
$25,515,208
Attributed
$25,837,435
Total exposure
19
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,837,435 · 19
By mechanism
U01$6,687,795 · 2
R01$4,616,214 · 4
U19$4,575,687 · 1
R33$3,219,120 · 2
R21$2,572,195 · 6
P01$2,416,255 · 1
Top collaborators
- Peter Fecci2 shared
Most similar at Duke University
Same institution · by research overlap
- David Reardon$8,732,934
- John H Sampson$43,413,436
- Gerald Arthur Grant$1,632,799
- Michael Rod Zalutsky$18,420,913
- Kyle D Allen$11,781,402
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseResponseCellsAntigensDendritic CellsLeadMonocyteDiagnosisInfectionSerumBloodAntibodiesLaboratoriesFutureCell TypeAffinityPhage DisplayImmuneImmune ResponseLibrariesToxic EffectDetectionDiagnosticSensitivity And Specificity
Grant awards (61)
Development of Diagnostic Antibodies for Acute and Chronic Chagas Disease$449,408
R21 · FY2025 · AI · contact PI
Development of point-of-care testing for Lassa and other hemorrhagic fever arenaviruses$398,606
R01 · FY2025 · AI · contact PI
Clinical Neuroimmunology of CCL3 in Brain Tumors$320,248
R01 · FY2025 · CA · contact PI
Development of point-of-care testing for Lassa and other hemorrhagic fever arenaviruses$413,856
R01 · FY2024 · AI · contact PI
Clinical Neuroimmunology of CCL3 in Brain Tumors$324,206
R01 · FY2024 · CA · contact PI
Development of point-of-care testing for Lassa and other hemorrhagic fever arenaviruses$396,959
R01 · FY2023 · AI · contact PI
A novel cellular tumor vaccine strategy for mutant IDH1 glioma$291,202
P50 · FY2023 · CA · contact PI
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma$564,673
P01 · FY2022 · CA · contact PI
Development of point-of-care testing for Lassa and other hemorrhagic fever arenaviruses$396,959
R01 · FY2022 · AI · contact PI
A novel cellular tumor vaccine strategy for mutant IDH1 glioma$287,291
P50 · FY2022 · CA · contact PI
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma$565,823
P01 · FY2021 · CA · contact PI
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens$197,276
R21 · FY2021 · AI · contact PI
A novel cellular tumor vaccine strategy for mutant IDH1 glioma$167,921
P50 · FY2021 · CA · contact PI
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma$521,167
P01 · FY2020 · CA · contact PI
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens$237,672
R21 · FY2020 · AI · contact PI
A novel cellular tumor vaccine strategy for mutant IDH1 glioma$229,567
P50 · FY2020 · CA · contact PI
A novel cellular tumor vaccine strategy for mutant IDH1 glioma$160,934
P50 · FY2020 · CA · contact PI
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma$430,716
P01 · FY2019 · CA · contact PI
A novel cellular tumor vaccine strategy for mutant IDH1 glioma$247,407
P50 · FY2019 · CA · contact PI
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma$333,876
P01 · FY2018 · CA · contact PI
Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 Antibody$365,847
P50 · FY2017 · CA · contact PI
Generation of Zika virus-specific recombinant antibodies$198,750
R21 · FY2017 · AI · contact PI
Development of anti-Salmonella Single-chain Abs as serum diagnostics$1,094,892
R33 · FY2016 · AI · contact PI
Development of therapeutics for chlorine-induced airway and lung injury$743,914
U01 · FY2016 · ES · contact PI
Generation of Zika virus-specific recombinant antibodies$238,500
R21 · FY2016 · AI · contact PI
Development of therapeutics for chlorine-induced airway and lung injury$757,975
U01 · FY2015 · ES · contact PI
Development of anti-Salmonella Single-chain Abs as serum diagnostics$371,737
R33 · FY2015 · AI · contact PI
Development of therapeutics for chlorine-induced airway and lung injury$851,385
U01 · FY2014 · ES · contact PI
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics$450,686
R33 · FY2014 · AI · contact PI
Development of anti-Salmonella Single-chain Abs as serum diagnostics$422,690
R33 · FY2014 · AI · contact PI
Development of therapeutics for chlorine-induced airway and lung injury$863,454
U01 · FY2013 · ES · contact PI
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics$416,644
R33 · FY2013 · AI · contact PI
Development of anti-Salmonella Single-chain Abs as serum diagnostics$232,058
R21 · FY2013 · AI · contact PI
Development of therapeutics for chlorine-induced airway and lung injury$914,322
U01 · FY2012 · ES · contact PI
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics$462,471
R33 · FY2012 · AI · contact PI
Role of Vascular Dendritic Cells in Atherosclerosis$308,880
R01 · FY2012 · HL · contact PI
Development of anti-Salmonella Single-chain Abs as serum diagnostics$193,754
R21 · FY2012 · AI · contact PI
Role of Vascular Dendritic Cells in Atherosclerosis$312,000
R01 · FY2011 · HL · contact PI
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics$219,416
R21 · FY2011 · AI · contact PI
Prevention of Inflammatory Lung Injury After Chlorine Exposure$78,500
U01 · FY2011 · ES · contact PI
Prevention of Inflammatory Lung Injury After Chlorine Exposure$404,275
U01 · FY2010 · ES · contact PI
Role of Vascular Dendritic Cells in Atherosclerosis$312,000
R01 · FY2010 · HL · contact PI
Prevention of Inflammatory Lung Injury After Chlorine Exposure$195,366
U01 · FY2010 · ES · contact PI
Development of anti-Aspergillus single chain Abs as serum and imaging diagnostics$189,961
R21 · FY2010 · AI · contact PI
Prevention of Inflammatory Lung Injury After Chlorine Exposure$396,465
U01 · FY2009 · ES · contact PI
Prevention of Immune Pathology during Avian Influenza Infection$382,590
U01 · FY2009 · AI · contact PI
Role of Vascular Dendritic Cells in Atherosclerosis$312,000
R01 · FY2009 · HL · contact PI
Prevention of Inflammatory Lung Injury After Chlorine Exposure$401,764
U01 · FY2008 · ES · contact PI
Prevention of Immune Pathology during Avian Influenza Infection$382,590
U01 · FY2008 · AI · contact PI
Role of Vascular Dendritic Cells in Atherosclerosis$312,000
R01 · FY2008 · HL · contact PI
Novel TLR Ligand Mimetics as Adjuvants and Therapeutics$970,322
U19 · FY2007 · AI · contact PI
Prevention of Immune Pathology during Avian Influenza Infection$315,195
U01 · FY2007 · AI · contact PI
Novel TLR Ligand Mimetics as Adjuvants and Therapeutics$970,200
U19 · FY2006 · AI · contact PI
Novel TLR Ligand Mimetics as Adjuvants and Therapeutics$964,605
U19 · FY2005 · AI
Novel TLR Ligand Mimetics as Adjuvants and Therapeutics$936,517
U19 · FY2004 · AI
The Role of Chemokines in Antigen-Specific Immunity$269,500
R01 · FY2004 · AI
Ablation of Stem Cell Progeny Regulating Atherosclerosis$192,500
R21 · FY2004 · EB
Novel TLR Ligand Mimetics as Adjuvants and Therapeutics$734,043
U19 · FY2003 · AI
The Role of Chemokines in Antigen-Specific Immunity$269,500
R01 · FY2003 · AI
Ablation of Stem Cell Progeny Regulating Atherosclerosis$222,900
R21 · FY2003 · EB
The Role of Chemokines in Antigen-Specific Immunity$269,500
R01 · FY2002 · AI